Biases in Medication Prescribing: The Case of Second-Generation Antipsychotics

  title={Biases in Medication Prescribing: The Case of Second-Generation Antipsychotics},
  author={Michael Makhinson},
  journal={Journal of Psychiatric Practice},
  • M. Makhinson
  • Published 1 January 2010
  • Psychology, Medicine
  • Journal of Psychiatric Practice
The shift from first-generation antipsychotic medications to second-generation antipsychotic medications initially caused a wave of excitement about the potential for improved and broader efficacy of these medications concurrent with an improved side-effect profile. Recent data from high-quality research analyses have subsequently raised significant questions about these claims. This research evidence has, however, not altered prescribing behavior in a way that would be expected from fully… 

The Ideal Antipsychotic: Hybrid between Typical Haloperidol And the Atypical Clozapine Antipsychotic

The design of a “hybrid structure” having the desired properties of haloperidol and clozapine is proposed, with the intention being to find an optimal antipsychotic agent that exerts efficient therapeutic effects against both positive and negative symptoms of psychosis causing least possible side effects, such as in monotherapy.

Bias , with a Focus on Psychiatry : Causes and Solutions

This paper reviews the topic of publication bias with a focus on drugs prescribed for psychiatric conditions, especially depression, schizophrenia, bipolar disorder, and autism, and it is suggested that journals borrow from the FDA review model.

Biases in the Evaluation of Psychiatric Clinical Evidence

  • M. Makhinson
  • Psychology
    The Journal of nervous and mental disease
  • 2012
This study focuses on the field of psychiatry and on the potentially significant implications of evidence biases for psychiatric practice and clinical understanding.

Publication Bias, with a Focus on Psychiatry: Causes and Solutions

This paper reviews the topic of publication bias with a focus on drugs prescribed for psychiatric conditions, especially depression, schizophrenia, bipolar disorder, and autism, and suggests that journals borrow from the FDA review model.

Commentary: The Public Health Consequences of an Industry-Influenced Psychiatric Taxonomy: “Attenuated Psychotic Symptoms Syndrome” as a Case Example

The first draft of DSM-V, recently made public, has created a firestorm of controversy, for the DSM's nomenclature of disease or other pathology not only affects such disparate domains as jurisprudence and insurance claims but is also an instrument designed to facilitate research on psychopathology.

On the Value of Evidence-Based Psychopharmacology Algorithms

The usefulness of EBM in the day-today practice of medicine and psychopharmacology is limited because it takes far too much time and requires use of cognitive processes that may be unfamiliar to some clinicians.

A Roadmap for Development of Novel Antipsychotic Agents Based on a Risperidone Scaffold

A ROADMAP FOR DEVELOPMENT OF NOVEL ANTIPSYCHOTIC AGENTS BASED ON A RISPERIDONE SCAFFOLD By Urjita H. Shah, Ph. D. A dissertation submitted in partial fulfillment of the requirements for the degree of

Current awareness in human psychopharmacology

  • Psychology
  • 2010
In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography

Evidence-informed person-centered healthcare part I: do 'cognitive biases plus' at organizational levels influence quality of evidence?

Qualitative evidence suggests that 'cognitive biases plus' can erode the quality of evidence, and social behavioural researchers advocate multi-pronged measures in similar situations.

Physicians under the Influence: Social Psychology and Industry Marketing Strategies

To illustrate how pharmaceutical marketing strategies use psychological techniques to promote targeted therapies, this work draws on the relevant social psychology literature on conflicts of interest and on the six principles of influence articulated by the eminent social psychologist Robert Cialdini.



Extrapyramidal side-effects of antipsychotics in a randomised trial

The incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second theses antipsychotic drugs in people with schizophrenia.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.

Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006.

Use of each antipsychotic newly marketed over eight years increased while use of risperidone was unchanged and use of olanzapine and the first-generation antipsychotics declined.

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

All antipsychotic treatment groups in all phases made modest improvements in psychosocial functioning, and more substantial improvements would likely require more intensive adjunctive psychossocial rehabilitation interventions.

The new and evolving pharmacotherapy of schizophrenia.

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo, and this risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.